XBIO 10-Q filed 2026-11-12 | Key takeaways
XBIO filed its 10-Q; the most relevant disclosure change is added Business combinations: Xenetic entered into a Share Exchange Agreement on September 14, 2026 to acquire Santersus AG, a Swiss biotech company focused on NET-targeting technologies, with Santersus shareholders expected to own approximately 85% of the combined company post-closing and. Customer concentration: Takeda Pharmaceutical Co. Ltd. represented 100% of revenue.
Key takeaways
Revenue: Q3 2026 royalty revenue decreased 29% year-over-year to $725 thousand from $1.0 million in Q3 2025, primarily due to positive royalty adjustments from certain countries in Q3 2025 that did not recur; nine-month revenue remained relatively flat at $2.2 million versus $2.2 million in the prior year period.
Net loss: Q3 2026 net loss widened to $1.7 million compared to $510 thousand in Q3 2025, while nine-month net loss increased to $3.1 million from $2.1 million, driven by higher general and administrative expenses related to the proposed Santersus acquisition.
Liquidity: Cash declined to $5.8 million at September 30, 2026 from $7.9 million at December 31, 2025; working capital decreased to $4.1 million from $7.1 million primarily due to the net loss for the nine-month period.
M&A transaction: On September 14, 2026, Xenetic entered into a Share Exchange Agreement to acquire Santersus AG, a Swiss biotech focused on NET-targeting technologies, with closing subject to stockholder approval, regulatory clearance, and other customary conditions; a termination fee of $500,000 would be payable by Xenetic under specified circumstances.
Ownership restructure: Post-closing, Santersus shareholders are expected to own approximately 85% of the combined company with existing Xenetic stockholders owning approximately 15% on a fully diluted basis; the combined company would be renamed Santersus Bio, Inc. and trade under ticker SNTS.
Related party disclosure: Certain Xenetic directors, including Chairman Dr. Dmitry Genkin and director Mr. Moshe Mizrahy, are affiliated with Santersus, with Dr. Genkin being a founder, approximately 21% owner, board member, and Chief Scientific Officer of Santersus; the transaction was evaluated and approved by a Special Committee of independent directors.
Capital structure changes: All Series B Preferred Stock was converted to common stock during the nine months ended September 30, 2026, eliminating the preferred stock outstanding; warrants to purchase approximately 800 shares expired on July 3, 2026 and were forfeited.
Key metrics
Customer concentration
Disclosure changes
- Business combinations
Xenetic entered into a Share Exchange Agreement on September 14, 2026 to acquire Santersus AG, a Swiss biotech company focused on NET-targeting technologies, with Santersus shareholders expected to own approximately 85% of the combined company post-closing and the combined entity to trade as Santersus Bio, Inc. under ticker SNTS on Nasdaq.
This is a transformative transaction that would result in a change of control, with Xenetic stockholders retaining only approximately 15% ownership in the combined company; the transaction involves related parties and requires stockholder approval. - Related party transactions
Certain Xenetic directors, including Chairman Dr. Dmitry Genkin and director Mr. Moshe Mizrahy, are affiliated with Santersus AG; Dr. Genkin is a founder, approximately 21% owner, board member, and Chief Scientific Officer of Santersus, while Mr. Mizrahy is an approximately 11% owner and board member of Santersus; the transaction was evaluated by a Special Committee of independent directors.
Related party nature of the transaction creates potential conflicts of interest; independent Special Committee approval and independent financial advisor consultation were conducted to address these conflicts. - Stockholders' equity
All Series B Preferred Stock (approximately 1.5 million shares convertible into 45,000 shares of common stock) was converted to common stock during the nine months ended September 30, 2026; no preferred stock is outstanding as of September 30, 2026.
Complete conversion of preferred stock eliminates preferred stock as a separate class of equity and simplifies the capital structure. - Warrants
Warrants to purchase approximately 800 shares of common stock with an exercise price of $29.09 per share expired on July 3, 2026 and were forfeited during the three and nine months ended September 30, 2026.
Expiration of all outstanding warrants eliminates potential dilution from this source. - General and administrative expenses
General and administrative expenses increased by approximately $1.1 million (138.4%) to $1.9 million for Q3 2026 and by $1.5 million (72.4%) to $3.7 million for 9M 2026, primarily due to increases in legal and financial advisory services related to the proposed Acquisition with Santersus.
Significant increase in G&A expenses due to M&A activity impacts operating losses and cash burn; investors should monitor these costs as the transaction progresses. - Risk factors
The Q3 2026 10-Q includes extensive new risk factor disclosures related to the Santersus Acquisition, including risks related to stockholder approval, exchange ratio adjustments, termination fees, change of control, potential delisting, and conflicts of interest involving related parties.
The extensive acquisition-related risk disclosures highlight the significant uncertainties and potential adverse outcomes associated with this transaction for existing Xenetic stockholders.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow XBIO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.